Trevi Therapeutics stock soars on Phase 2a chronic cough data
Trevi Therapeutics’ chronic cough drug reduced patients’ 24-hour cough frequency by 57% compared to placebo in a Phase 2a trial, exceeding investors’ expectations. The company’s stock {$TRVI} soared 40% at market open as a result ...
Trevi Therapeutics’ chronic cough drug reduced patients’ 24-hour cough frequency by 57% compared to placebo in a Phase 2a trial, exceeding investors’ expectations.
The company’s stock {$TRVI} soared 40% at market open as a result ...
